Program
depemokimab
Also written as “Depemokimab”, “GSK3511294 (Depemokimab)” and “Depemokimab (GSK3511294)”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Nasal Polyps · Hypereosinophilic Syndrome · Churg-Strauss Syndrome, led by GlaxoSmithKline.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 189 open or running | phase 4since Jul 9, 2026 | Sep 15, 2017 | Mar 1, 2027phase 3 · NCT07671001 |
Also a collaborator on its studies: ppd-development-lp and iqvia-pty-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 15, 2017First study: phase 1 study in AsthmaFirst studyNCT03287310 · 50 enrolled · Germany, United Kingdom
- Jan 18, 20213 phase 3 studies in AsthmaNCT04719832, NCT04718389, NCT04718103
- Nov 22, 2021Phase 1 study in AsthmaNCT05140200 · 20 enrolled · China
- Feb 8, 20222 phase 3 studiesNCT05243680, NCT05263934
- Mar 2, 20222 phase 3 studies in Nasal PolypsNCT05274750, NCT05281523
- Apr 12, 2022Phase 3 study in Hypereosinophilic SyndromeNCT05334368 · 110 enrolled · United States, Argentina, Australia and more
- Oct 27, 2022Phase 1 study in AsthmaNCT05602025 · 140 enrolled · United States
- Apr 28, 20252 phase 3 studies in Pulmonary Disease, Chronic ObstructiveNCT06959095, NCT06961214
- May 16, 2025Phase 3 study in AsthmaNCT06979323 · 150 planned · United States, Belgium, Canada and more
- Sep 15, 2025Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07177339 · 1,196 planned · United States, Australia, Bulgaria and more
- Mar 2, 2026Phase 3 study in AsthmaNCT07456033 · 456 planned · United States, United Kingdom
- Jun 22, 2026Phase 3 study in AsthmaNCT07671001 · 34 planned · United States
- Jul 9, 2026Phase 4 study in Nasal PolypsNCT07701967 · 28 planned · Japan
Ahead
- Mar 1, 2027Primary completion: phase 3 study in AsthmaNCT07671001
- Jun 28, 2027Primary completion: phase 4 study in Nasal PolypsNCT07701967
- Oct 29, 2027Primary completion: phase 3 study in Hypereosinophilic SyndromeNCT05334368
- Jan 5, 2028Primary completion: phase 3 study in AsthmaNCT06979323
TargetBeta
“Interleukin-5 inhibitor”ChEMBL 37, by rule
Other programs on IL5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| SHR-1703 | Jiangsu HengRui Medicine | phase 3 | 7 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07701967Nasal Polyps · Japan | 4 | Recruiting | Jun 28, 2027 | 28 |
| NCT07671001Asthma · United States | 3 | Recruiting | Mar 1, 2027 | 34 |
| NCT07456033Asthma · United States, United Kingdom | 3 | Recruiting | Sep 23, 2030 | 456 |
| NCT07177339Pulmonary Disease, Chronic Obstructive · United States, Australia, Bulgaria and more | 3 | Recruiting | Apr 30, 2029 | 1,196 |
| NCT06979323Asthma · United States, Belgium, Canada and more | 3 | Recruiting | Jan 5, 2028 | 150 |
| NCT06961214Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Recruiting | Dec 13, 2028 | 961 |
| NCT06959095Pulmonary Disease, Chronic Obstructive · United States, Argentina, Belgium and more | 3 | Recruiting | Dec 13, 2028 | 981 |
| NCT05602025Asthma · United States | 1 | Completed | Oct 23, 2023 | 140 |
| NCT05334368Hypereosinophilic Syndrome · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 29, 2027 | 110 |
| NCT05281523Nasal Polyps · United States, China, Italy and more | 3 | Completed | Jul 12, 2024 | 264 |
| NCT05274750Nasal Polyps · United States, Argentina, Belgium and more | 3 | Completed | Jul 30, 2024 | 276 |
| NCT05263934Churg-Strauss Syndrome · United States, Argentina, Austria and more | 3 | Active, not recruiting | Sep 29, 2026 | 163 |
| NCT05243680Asthma · United States, Australia, Canada and more | 3 | Completed | May 19, 2025 | 641 |
| NCT05140200Asthma · China | 1 | Completed | Dec 23, 2022 | 20 |
| NCT04719832Asthma · United States, Canada, China and more | 3 | Completed | Nov 21, 2023 | 395 |
| NCT04718389Asthma · United States, Australia, Austria and more | 3 | Completed | Sep 14, 2025 | 1,717 |
| NCT04718103Asthma · United States, Australia, Canada and more | 3 | Completed | Apr 11, 2024 | 397 |
| NCT03287310Asthma · Germany, United Kingdom | 1 | Completed | Jul 31, 2019 | 50 |
How it is read
Names in the registry
- “Depemokimab”, 11 entries
- “GSK3511294 (Depemokimab)”, 3 entries
- “Depemokimab (GSK3511294)”, 2 entries
- “GSK3511294”, 2 entries
Conditions, from the studies’ own filings
- Asthma, 10 studies
- Pulmonary Disease, Chronic Obstructive, 3 studies
- Nasal Polyps, 3 studies
- Hypereosinophilic Syndrome, 1 study
- Churg-Strauss Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.